GO
Loading...

Amgen Inc

More

  • Final Glance: Biotechnology companies Monday, 24 Nov 2014 | 6:08 PM ET

    Amgen Inc. rose $1.37 or. 8 percent, to $164.18. Biogen Idec rose $3.19 or 1.1 percent, to $306.74. Celgene Corp. rose $2.78 or 2.6 percent, to $110.98.

  • Early Glance: Biotechnology companies Monday, 24 Nov 2014 | 10:26 AM ET

    Amgen Inc. rose $2.73 or 1.7 percent, to $165.54. Biogen Idec rose $3.62 or 1.2 percent, to $307.17. Celgene Corp. rose $2.12 or 2.0 percent, to $110.32.

  • Final Glance: Biotechnology companies Friday, 21 Nov 2014 | 6:02 PM ET

    Amgen Inc. rose$. 13 or. 1 percent, to $162.81. Biogen Idec rose $4.45 or 1.5 percent, to $303.55. Celgene Corp. rose$. 85 or. 8 percent, to $108.20.

  • Early Glance: Biotechnology companies Friday, 21 Nov 2014 | 10:17 AM ET

    Amgen Inc. fell$. 16 or. 1 percent, to $162.52. Biogen Idec rose $3.56 or 1.2 percent, to $302.66. Celgene Corp. rose $1.30 or 1.2 percent, to $108.65.

  • Final Glance: Biotechnology companies Thursday, 20 Nov 2014 | 6:02 PM ET

    Amgen Inc. rose$. 04 or percent, to $162.68. Biogen Idec fell $4.51 or 1.5 percent, to $299.10. Celgene Corp. rose$. 37 or. 3 percent, to $107.35.

  • Midday Glance: Biotechnology companies Thursday, 20 Nov 2014 | 2:49 PM ET

    Amgen Inc. rose $1.79 or 1.1 percent, to $164.43. Biogen Idec fell $1.84 or. 6 percent, to $301.78. Celgene Corp. rose$. 60 or. 6 percent, to $107.58.

  • Early Glance: Biotechnology companies Thursday, 20 Nov 2014 | 10:29 AM ET

    Amgen Inc. rose$. 44 or. 3 percent, to $163.08. Biogen Idec fell$. 30 or. 1 percent, to $303.31. Celgene Corp. fell$. 16 or. 2 percent, to $106.82.

  • Nov 20- Global pharmaceutical spending will break the trillion dollar mark in 2014, driven by high prices in the United States for novel treatments such as Gilead Sciences Inc's Sovaldi for hepatitis C and new cancer drugs, according to a study released on Thursday. Total spending on drugs will hit $1.06 trillion, an increase of 7 percent over 2013 levels,...

  • Final Glance: Biotechnology companies Wednesday, 19 Nov 2014 | 6:02 PM ET

    Amgen Inc. rose$. 40 or. 2 percent, to $162.64. Biogen Idec fell $1.95 or. 6 percent, to $303.61. Celgene Corp. rose$. 20 or. 2 percent, to $106.98.

  • Midday Glance: Biotechnology companies Wednesday, 19 Nov 2014 | 1:31 PM ET

    Amgen Inc. rose$. 39 or. 2 percent, to $162.63. Biogen Idec fell $1.63 or. 5 percent, to $303.93. Celgene Corp. rose$. 79 or. 7 percent, to $107.57.

  • Early Glance: Biotechnology companies Wednesday, 19 Nov 2014 | 12:00 PM ET

    Amgen Inc. fell $1.18 or. 7 percent, to $161.06. Biogen Idec fell $1.69 or. 6 percent, to $303.87. Celgene Corp. fell$. 80 or. 7 percent, to $105.98.

  • Final Glance: Biotechnology companies Tuesday, 18 Nov 2014 | 6:02 PM ET

    Amgen Inc. rose $3.10 or 1.9 percent, to $162.24. Biogen Idec rose $3.14 or 1.0 percent, to $305.56. Celgene Corp. rose $2.42 or 2.3 percent, to $106.78.

  • Midday Glance: Biotechnology companies Tuesday, 18 Nov 2014 | 1:24 PM ET

    Amgen Inc. rose $2.16 or 1.4 percent, to $161.30. Biogen Idec rose $2.95 or 1.0 percent, to $305.37. Celgene Corp. rose $2.53 or 2.4 percent, to $106.89.

  • Early Glance: Biotechnology companies Tuesday, 18 Nov 2014 | 10:23 AM ET

    Amgen Inc. rose$. 78 or. 5 percent, to $159.92. Biogen Idec rose $3.58 or 1.2 percent, to $306.00. Celgene Corp. rose $1.85 or 1.8 percent, to $106.21.

  • Final Glance: Biotechnology companies Monday, 17 Nov 2014 | 6:02 PM ET

    Amgen Inc. rose $1.46 or. 9 percent, to $159.14. Biogen Idec fell $3.01 or 1.0 percent, to $302.42. Celgene Corp. rose$. 31 or. 3 percent, to $104.36.

  • Midday Glance: Biotechnology companies Monday, 17 Nov 2014 | 2:21 PM ET

    Amgen Inc. rose $1.51 or 1.0 percent, to $159.19. Biogen Idec fell $1.03 or. 3 percent, to $304.40. Celgene Corp. rose$. 47 or. 5 percent, to $104.52.

  • CHICAGO, Nov 17- Regeneron Corp's experimental drug alirocumab helped 10 times as many high-risk patients unable to tolerate widely-used statins get their "bad" LDL cholesterol down to target levels than Merck& Co's Zetia, according to data from a clinical trial presented on Monday. Alirocumab, developed along with French drugmaker Sanofi, belongs to a new...

  • Early Glance: Biotechnology companies Monday, 17 Nov 2014 | 10:28 AM ET

    Amgen Inc. rose $1.55 or 1.0 percent, to $159.23. Biogen Idec rose $1.87 or. 6 percent, to $307.30. Celgene Corp. rose $1.12 or 1.1 percent, to $105.17.

  • Final Glance: Biotechnology companies Friday, 14 Nov 2014 | 6:03 PM ET

    Amgen Inc. fell $3.17 or 2.0 percent, to $157.68. Biogen Idec fell $12.55 or 3.9 percent, to $305.43. Celgene Corp. fell $3.38 or 3.1 percent, to $104.05.

  • Midday Glance: Biotechnology companies Friday, 14 Nov 2014 | 1:17 PM ET

    Amgen Inc. fell $3.32 or 2.1 percent, to $157.53. Biogen Idec fell $14.15 or 4.4 percent, to $303.83. Celgene Corp. fell $4.03 or 3.8 percent, to $103.40.